TY - JOUR
T1 - Gut microbial biomarkers for predicting adverse outcomes in people with chronic kidney disease
AU - Cooper, Tess E.
AU - Au, Eric H.
AU - Chung, Edmund Y.M.
AU - Tunnicliffe, David J.
AU - Craig, Jonathan C.
AU - Gesualdo, Loreto
AU - Howell, Martin
AU - Mannon, Peter
AU - Mannon, Roslyn
AU - Strippoli, Giovanni F.M.
AU - Teixeira-Pinto, Armando
AU - Tong, Allison
AU - Wong, Germaine
N1 - Funding Information:
G Wong is supported by an NHMRC Australia Investigator Grant APP1195414 National Health and Medical Research Council (NHMRC), Australia
Funding Information:
TC is supported under funding from this external grant
Funding Information:
We wish to acknowledge the assistance of the Cochrane Kidney and Transplant Information Specialist, Gail Higgins. We are grateful to the following peer reviewers for their time and comments and also to the one (1) peer reviewer who wishes to remain anonymous.?1. Sarah Hodgkinson, Associate Editor, Editorial and Methods Department, Cochrane?2. Andrea Iannone, Section of Gastroenterology, Department of Emergency and Organ Transplantation, University of Bari, Italy The Methods section of this protocol is based on a standard template developed by the Cochrane Prognosis Methods Group with adaptations for the Cochrane Kidney and Transplant group.
Publisher Copyright:
Copyright © 2022 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
PY - 2022/1/12
Y1 - 2022/1/12
N2 - Objectives: This is a protocol for a Cochrane Review (prognosis). The objectives are as follows:. To (a) identify the gut microbial biomarkers in patients with CKD, on dialysis, and with kidney transplants; (b) determine whether these biomarkers are associated independently with adverse patient-relevant outcomes leading to progression of CKD stages 1 to 5; and (c) explore sources of heterogeneity. Investigation of sources of heterogeneity between studies We will explore potential sources of heterogeneity that may impact outcomes such as differences in study participation; stage of CKD (KDIGO 2013; Appendix 1); study design (cohort, case series, case study), timing of outcome measurements; units and instruments of outcome measurements; and length of follow-up.
AB - Objectives: This is a protocol for a Cochrane Review (prognosis). The objectives are as follows:. To (a) identify the gut microbial biomarkers in patients with CKD, on dialysis, and with kidney transplants; (b) determine whether these biomarkers are associated independently with adverse patient-relevant outcomes leading to progression of CKD stages 1 to 5; and (c) explore sources of heterogeneity. Investigation of sources of heterogeneity between studies We will explore potential sources of heterogeneity that may impact outcomes such as differences in study participation; stage of CKD (KDIGO 2013; Appendix 1); study design (cohort, case series, case study), timing of outcome measurements; units and instruments of outcome measurements; and length of follow-up.
UR - http://www.scopus.com/inward/record.url?scp=85122767023&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85122767023&partnerID=8YFLogxK
U2 - 10.1002/14651858.CD014786
DO - 10.1002/14651858.CD014786
M3 - Article
AN - SCOPUS:85122767023
VL - 2022
JO - The Cochrane database of systematic reviews
JF - The Cochrane database of systematic reviews
SN - 1361-6137
IS - 1
M1 - CD014786
ER -